Monoamine oxidase: multiple forms and selective inhibitors.
Reads0
Chats0
About:
This article is published in Biochemical Journal.The article was published on 1971-02-01 and is currently open access. It has received 28 citations till now. The article focuses on the topics: Tranylcypromine & Monoamine oxidase B.read more
Citations
More filters
Journal ArticleDOI
Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
TL;DR: Results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons, the first anti-Parkinson drug having such a property.
Journal ArticleDOI
Oxidative stress and antioxidant therapy in Parkinson's disease
TL;DR: Experimental therapeutic refinements to attenuate the effects of oxidative stress and to provide neuroprotection of striatal dopaminergic neurons in Parkinson's disease include blocking dopamine transporter by mazindol, blocking NMDA receptors by dizocilpine maleate, enhancing the survival of neurons by giving brain-derived neurotrophic factors, providing antioxidants such as vitamin E, or inhibiting monoamine oxidase B by selegiline.
Journal ArticleDOI
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.
TL;DR: Deprenil is an inhibitor of MAO-B and is characterized by less frequent side effects, which can be eliminated by lowering the dosage of Deprenil, which is an excellent drug for preventing these.
Journal ArticleDOI
Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’
J. D. Elsworth,Vivette Glover,Gavin P. Reynolds,M. Sandler,Andrew J. Lees,P. Phuapradit,K.M. Shaw,G. M. Stern,Parveen Kumar +8 more
TL;DR: Oral phenylethylamine challenge with amounts greater than those known to be present in a normal diet similarly gave rise to no adverse reaction in (-)-deprenyl-treated subjects; the reasons for this remain to be determined.
Journal ArticleDOI
A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety.
TL;DR: The correlates of response and the results of the clinical ratings suggest that phenelzine is not acting as an antidepressant in this population of chronic agoraphobic and socially phobic psychiatric out-patients.